Beginning with our fourth quarter results, we finished the quarter with adjusted diluted earnings per share of $2.39, an increase of 26.5%, which was driven by both a full quarter's worth of contribution from Alliance Healthcare and the strong performance in our Pharmaceutical Distribution Services segment.
